Johnson & Johnson: A Strong Dividend Safety Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy JNJ?
Source: Fool
- Dividend Growth Stability: Johnson & Johnson has increased its dividend for 64 consecutive years, establishing itself as a Dividend King, which demonstrates exceptional stability in dividend payments and attracts long-term investors.
- Cash Flow to Dividend Ratio: Last year, Johnson & Johnson reported $20.4 billion in free cash flow against $12.4 billion in dividends, resulting in a strong 61% ratio that indicates robust dividend-paying capacity and reflects the company's financial health.
- Market Performance and Yield: With a dividend yield of 2.31% and an average of 2.7% over the past decade, significantly above the market average, Johnson & Johnson enhances its appeal as an investment choice for income-focused investors.
- Strong Financial Resources: As of the end of Q1, Johnson & Johnson held $21.7 billion in cash and cash equivalents, ensuring its ability to maintain dividend payments, which further solidifies investor confidence in its dividend safety.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 222.510
Low
190.00
Averages
218.50
High
240.00
Current: 222.510
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Deputy Commissioner Considered for Acting Commissioner Role
- Acting Commissioner Candidates: FDA Deputy Commissioner Kyle Diamantas is being considered for the acting commissioner role as current Commissioner Marty Makary's tenure is reportedly ending soon, which could impact the agency's policy direction and operational efficiency.
- Additional Candidates: Alongside Diamantas, Deputy Commissioner for Policy, Legislation, and International Affairs Grace Graham and senior counselor to HHS Secretary Robert F. Kennedy Jr., Sara Brenner, are also in the running, indicating a diverse consideration for FDA leadership.
- Former Commissioners Considered: Former FDA Commissioner Stephen Hahn and former acting commissioner and Assistant Health Secretary Brett Giroir are being considered for a permanent role, suggesting a potential return to a more traditional leadership style at the FDA.
- Industry Implications: Changes in FDA leadership may affect pharmaceutical companies like Pfizer, particularly in terms of policy formulation and regulatory enforcement, which could influence drug approvals and market strategies.
See More
Trump Signs Proposal to Oust FDA Commissioner Makary Amid Turmoil
- FDA Leadership Change: President Trump has signed a proposal to oust FDA Commissioner Marty Makary due to perceived management failures, leading to clashes with HHS officials and the White House, indicating dissatisfaction within the Trump administration regarding FDA leadership.
- High-Level Departures: Makary's potential removal marks him as another high-profile health official to exit under Trump, following CDC Director Susan Monarez, reflecting a tumultuous period for the FDA that could undermine the agency's stability.
- Industry Reactions: White House officials believe Makary's departure stems from chaos within the FDA and increasing complaints from the pharmaceutical industry, highlighting concerns over the agency's management efficiency that may influence future FDA policies.
- Appointment Context: Nominated by Trump in November 2024 to succeed Robert Califf, Makary's controversial tenure has raised questions about the Trump administration's reputation in public health, potentially impacting its standing with stakeholders.
See More
Three Unstoppable Dividend Kings to Buy Now
- Strong Dividend Growth: Johnson & Johnson (JNJ) raised its dividend by 3.1% last month, marking 64 consecutive years of increases, with a current yield of 2.3%, significantly higher than the S&P 500's 1.1%, demonstrating its stability and appeal during economic downturns.
- Robust Cash Flow: Johnson & Johnson generated $20 billion in free cash flow last year, more than covering its $12.4 billion dividend payout, and its ultra-low net debt level underscores its financial health and ability to sustain dividends.
- Long-Term Growth Potential: Procter & Gamble (PG) has paid dividends for 136 consecutive years, recently extending its growth streak to 70 years, with expected operating cash flow of $20 billion this year, sufficient to cover its $10 billion dividend and $5 billion in share repurchases, ensuring stable dividend payments.
- Strategic Investments and Returns: PepsiCo (PEP) delivered a 4% dividend increase this year and plans to return about $8.9 billion in cash to shareholders, showcasing its strong cash flow and strategic investment capabilities, which are expected to support long-term revenue growth and dividend increases.
See More
Market Dynamics: Oil Prices and Tech Stocks Fluctuate
- Oil Price Recovery: West Texas Intermediate crude oil prices rebounded above $97 per barrel after a morning dip, reflecting cautious optimism about future demand, which could impact related energy stocks' performance.
- Divergent Tech Stock Performance: As AI-related stocks pull back, cybersecurity software stocks like CrowdStrike and Palo Alto Networks surged, crossing $500 and $190 respectively for the first time, indicating increased market confidence in their business models and potentially attracting more investor interest.
- Boeing Stock Rise: Boeing's shares rose as CEO Kelly Ortberg is set to accompany President Trump on his trip to China, with the market anticipating a major order of up to 500 planes, although skepticism remains regarding the order's realization.
- Employment Data Expectations: Economists forecast a 65,000 increase in April's nonfarm payrolls with the unemployment rate steady at 4.3%, while average hourly earnings are expected to rise by 3.8%, providing crucial economic health indicators that could influence investor confidence.
See More
Dividend Stocks Comparison: Johnson & Johnson vs. AbbVie
- Diversification Advantage: Johnson & Johnson's diversified operations in pharmaceuticals and medical devices allow it to maintain stability in a competitive market, with revenue growth despite losing Stelara's patent, and it is projected to reach $100 billion in revenue by 2026, becoming only the second biopharma to achieve this milestone in history.
- Core Growth Drivers for AbbVie: AbbVie's leadership in immunology led to $15 billion in revenue in Q1, a 12.4% year-over-year increase, with Skyrizi and Rinvoq contributing $6.6 billion, showcasing strong market performance, though it faces competitive risks.
- Dividend Growth History: Johnson & Johnson has raised its dividends for 64 consecutive years compared to AbbVie's 54 years, indicating stronger financial stability and long-term investment appeal, particularly in the current market environment, with its AAA credit rating further enhancing its attractiveness as a low-risk investment.
- Market Risks and Opportunities: While Johnson & Johnson faces litigation risks related to its talc products, its diversified portfolio enables it to navigate challenges like drug pricing negotiations, whereas AbbVie shows potential in new product launches, especially with its weight-loss treatment performing well in clinical trials.
See More
Johnson & Johnson: A Strong Dividend Safety Analysis
- Dividend Growth Stability: Johnson & Johnson has increased its dividend for 64 consecutive years, establishing itself as a Dividend King, which demonstrates exceptional stability in dividend payments and attracts long-term investors.
- Cash Flow to Dividend Ratio: Last year, Johnson & Johnson reported $20.4 billion in free cash flow against $12.4 billion in dividends, resulting in a strong 61% ratio that indicates robust dividend-paying capacity and reflects the company's financial health.
- Market Performance and Yield: With a dividend yield of 2.31% and an average of 2.7% over the past decade, significantly above the market average, Johnson & Johnson enhances its appeal as an investment choice for income-focused investors.
- Strong Financial Resources: As of the end of Q1, Johnson & Johnson held $21.7 billion in cash and cash equivalents, ensuring its ability to maintain dividend payments, which further solidifies investor confidence in its dividend safety.
See More
FDA Deputy Commissioner Considered for Acting Commissioner Role
- Acting Commissioner Candidates: FDA Deputy Commissioner Kyle Diamantas is being considered for the acting commissioner role as current Commissioner Marty Makary's tenure is reportedly ending soon, which could impact the agency's policy direction and operational efficiency.
- Additional Candidates: Alongside Diamantas, Deputy Commissioner for Policy, Legislation, and International Affairs Grace Graham and senior counselor to HHS Secretary Robert F. Kennedy Jr., Sara Brenner, are also in the running, indicating a diverse consideration for FDA leadership.
- Former Commissioners Considered: Former FDA Commissioner Stephen Hahn and former acting commissioner and Assistant Health Secretary Brett Giroir are being considered for a permanent role, suggesting a potential return to a more traditional leadership style at the FDA.
- Industry Implications: Changes in FDA leadership may affect pharmaceutical companies like Pfizer, particularly in terms of policy formulation and regulatory enforcement, which could influence drug approvals and market strategies.
See More
Trump Signs Proposal to Oust FDA Commissioner Makary Amid Turmoil
- FDA Leadership Change: President Trump has signed a proposal to oust FDA Commissioner Marty Makary due to perceived management failures, leading to clashes with HHS officials and the White House, indicating dissatisfaction within the Trump administration regarding FDA leadership.
- High-Level Departures: Makary's potential removal marks him as another high-profile health official to exit under Trump, following CDC Director Susan Monarez, reflecting a tumultuous period for the FDA that could undermine the agency's stability.
- Industry Reactions: White House officials believe Makary's departure stems from chaos within the FDA and increasing complaints from the pharmaceutical industry, highlighting concerns over the agency's management efficiency that may influence future FDA policies.
- Appointment Context: Nominated by Trump in November 2024 to succeed Robert Califf, Makary's controversial tenure has raised questions about the Trump administration's reputation in public health, potentially impacting its standing with stakeholders.
See More
Three Unstoppable Dividend Kings to Buy Now
- Strong Dividend Growth: Johnson & Johnson (JNJ) raised its dividend by 3.1% last month, marking 64 consecutive years of increases, with a current yield of 2.3%, significantly higher than the S&P 500's 1.1%, demonstrating its stability and appeal during economic downturns.
- Robust Cash Flow: Johnson & Johnson generated $20 billion in free cash flow last year, more than covering its $12.4 billion dividend payout, and its ultra-low net debt level underscores its financial health and ability to sustain dividends.
- Long-Term Growth Potential: Procter & Gamble (PG) has paid dividends for 136 consecutive years, recently extending its growth streak to 70 years, with expected operating cash flow of $20 billion this year, sufficient to cover its $10 billion dividend and $5 billion in share repurchases, ensuring stable dividend payments.
- Strategic Investments and Returns: PepsiCo (PEP) delivered a 4% dividend increase this year and plans to return about $8.9 billion in cash to shareholders, showcasing its strong cash flow and strategic investment capabilities, which are expected to support long-term revenue growth and dividend increases.
See More
Market Dynamics: Oil Prices and Tech Stocks Fluctuate
- Oil Price Recovery: West Texas Intermediate crude oil prices rebounded above $97 per barrel after a morning dip, reflecting cautious optimism about future demand, which could impact related energy stocks' performance.
- Divergent Tech Stock Performance: As AI-related stocks pull back, cybersecurity software stocks like CrowdStrike and Palo Alto Networks surged, crossing $500 and $190 respectively for the first time, indicating increased market confidence in their business models and potentially attracting more investor interest.
- Boeing Stock Rise: Boeing's shares rose as CEO Kelly Ortberg is set to accompany President Trump on his trip to China, with the market anticipating a major order of up to 500 planes, although skepticism remains regarding the order's realization.
- Employment Data Expectations: Economists forecast a 65,000 increase in April's nonfarm payrolls with the unemployment rate steady at 4.3%, while average hourly earnings are expected to rise by 3.8%, providing crucial economic health indicators that could influence investor confidence.
See More
Dividend Stocks Comparison: Johnson & Johnson vs. AbbVie
- Diversification Advantage: Johnson & Johnson's diversified operations in pharmaceuticals and medical devices allow it to maintain stability in a competitive market, with revenue growth despite losing Stelara's patent, and it is projected to reach $100 billion in revenue by 2026, becoming only the second biopharma to achieve this milestone in history.
- Core Growth Drivers for AbbVie: AbbVie's leadership in immunology led to $15 billion in revenue in Q1, a 12.4% year-over-year increase, with Skyrizi and Rinvoq contributing $6.6 billion, showcasing strong market performance, though it faces competitive risks.
- Dividend Growth History: Johnson & Johnson has raised its dividends for 64 consecutive years compared to AbbVie's 54 years, indicating stronger financial stability and long-term investment appeal, particularly in the current market environment, with its AAA credit rating further enhancing its attractiveness as a low-risk investment.
- Market Risks and Opportunities: While Johnson & Johnson faces litigation risks related to its talc products, its diversified portfolio enables it to navigate challenges like drug pricing negotiations, whereas AbbVie shows potential in new product launches, especially with its weight-loss treatment performing well in clinical trials.
See More
Johnson & Johnson: A Strong Dividend Safety Analysis
- Dividend Growth Stability: Johnson & Johnson has increased its dividend for 64 consecutive years, establishing itself as a Dividend King, which demonstrates exceptional stability in dividend payments and attracts long-term investors.
- Cash Flow to Dividend Ratio: Last year, Johnson & Johnson reported $20.4 billion in free cash flow against $12.4 billion in dividends, resulting in a strong 61% ratio that indicates robust dividend-paying capacity and reflects the company's financial health.
- Market Performance and Yield: With a dividend yield of 2.31% and an average of 2.7% over the past decade, significantly above the market average, Johnson & Johnson enhances its appeal as an investment choice for income-focused investors.
- Strong Financial Resources: As of the end of Q1, Johnson & Johnson held $21.7 billion in cash and cash equivalents, ensuring its ability to maintain dividend payments, which further solidifies investor confidence in its dividend safety.
See More
